Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$98.95 USD

98.95
124,719

+2.28 (2.36%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $98.95 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Believe Ligand (LGND) Could Rally 38.66%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Ligand (LGND) points to a 38.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down

by Zacks Equity Research

Bausch (BHC) declines as it misses on earnings and sales in the first quarter.

Best Momentum Stocks to Buy for May 5th

by Zacks Equity Research

VREX, LGND and FLS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 5, 2023.

New Strong Buy Stocks for May 5th

by Zacks Equity Research

VREX, LGND, RNGR, SIGA and KMT have been added to the Zacks Rank #1 (Strong Buy) List on May 5, 2023.

Ligand Pharmaceuticals (LGND) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 121.36% and 12.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses

by Zacks Equity Research

FATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023.

Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.

Shaun Pruitt headshot

2 Medical Stocks to Buy Before Earnings

by Shaun Pruitt

Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their quarterly reports.

Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.

Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.

LGND vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

LGND vs. REGN: Which Stock Is the Better Value Option?

ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake Encouraging

by Zacks Equity Research

ImmunoGen (IMGN) reports impressive Q1 earnings results on strong adoption of sole-marketed drug Elahere. The company raises financial guidance for 2023. Post the news, shares moved up 25%.

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.

BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.

Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo

by Zacks Equity Research

Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Roche (RHHBY) Polivy Combination for DLBCL Gets Full Approval

by Zacks Equity Research

Roche (RHHBY) gets full approval for Polivy (polatuzumab vedotin-piiq) in combination with Rituxan, cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated DLBCL.

Does Ligand (LGND) Have the Potential to Rally 41.24% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Ligand (LGND) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data

by Zacks Equity Research

Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older.

Bristol Myers (BMY), TSVT Application for Abecma Accepted

by Zacks Equity Research

Bristol Myers (BMY) and partner TSVTs sBLA for CAR T cell therapy is accepted by the FDA for earlier lines of treatment in multiple myeloma.

Roche (RHHBY) Announces Data on Tecentriq Combo for HCC

by Zacks Equity Research

Roche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of Tecentriq and Avastin reduces the risk of cancer relapsing in people with certain types of adjuvant liver cancer in a phase III study.

Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence

by Zacks Equity Research

Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.

Is Hologic (HOLX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Hologic (HOLX) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.